Liver Cell Type-Specific Targeting by Nanoformulations for Therapeutic Applications

Area of Science:

• Hepatology
• Immunology
• Nanomedicine

Background:

• The liver's dual role in metabolism and immune tolerance makes it a key therapeutic target.
• Liver disorders encompass metabolic diseases, immunological conditions, viral hepatitis, and cancer.
• Non-parenchymal liver cells (NPCs) are crucial for immune tolerance, presenting challenges for therapeutic interventions.

Purpose of the Study:

• To review current preclinical nanodrug-based strategies for treating diverse liver disorders.
• To highlight the application of nanotechnology in modulating liver immunity and targeting liver pathologies.
• To summarize advancements in nanomedicine for hepatitis, liver cancer, and inflammatory/autoimmune liver diseases.

Main Methods:

• Review of preclinical studies on nanodrugs for liver disease treatment.
• Analysis of nano-vaccines and adjuvants for chronic hepatitis.
• Examination of nanodrugs targeting liver cancer cells and tumor microenvironment.
• Investigation of nanoparticle-encapsulated anti-inflammatory agents.
• Exploitation of liver sinusoidal cells (LSECs) for tolerance induction.

Main Results:

• Nano-vaccines and adjuvants show potential for hepatitis treatment by modulating immune responses.
• Nanodrugs can selectively target and eliminate liver cancer cells.
• Nanomedicines can reprogram or deplete immunosuppressive cells in the liver tumor microenvironment, with combination therapies showing synergistic effects.
• Encapsulating anti-inflammatory agents in nanoparticles reduces inflammation in liver diseases.
• Leveraging LSECs facilitates antigen-specific tolerance for allergic and autoimmune diseases.

Conclusions:

• Nanodrugs represent a promising therapeutic avenue for a wide spectrum of liver disorders.
• Targeted delivery and immune modulation via nanomedicine offer novel treatment strategies for liver diseases.
• Nanotechnology holds potential for developing effective treatments for hepatitis, liver cancer, and immune-mediated liver conditions.